ArticleJCEM case reports2025
Association of Central Serous Chorioretinopathy With Endogenous or Exogenous Corticosteroids: A Report of 2 Cases.
Article in JCEM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to elucidate the potential relationship between central serous chorioretinopathy (CSC) and both endogenous hypercortisolism and the administration of exogenous corticosteroids. Case 1 involved a 39-year-old female patient who presented with blurred vision and metamorphopsia. Ophthalmologic examinations confirmed bilateral CSC. Biochemical and clinical evidence suggested hypercortisolism, and abdominal computed tomography revealed an adrenal adenoma, leading to a diagnosis of adrenocorticotropin-independent Cushing syndrome (CS). Postoperatively, a regression of serous retinal detachments was observed within 6 weeks. Case 2 referred to a 60-year-old male patient with hyperthyroidism and Graves orbitopathy who experienced vision loss after intravenous administration of 4.5 g of methylprednisolone over 10 weeks. Vision deteriorated after glucocorticoid therapy but improved 6 months later on discontinuation. Subsequently, the patient received peribulbar injections of triamcinolone acetonide, resulting in acute vision loss, with ophthalmologic examinations confirming CSC. After the cessation of exogenous corticosteroids, CSC resolved, and retinal pigment epithelium detachment also resolved at 3 months. Although causality cannot be definitively established with only 2 cases, the spontaneous resolution of subretinal fluid following corticosteroid withdrawal is highly indicative. The use of both endogenous hypercortisolism and exogenous corticosteroids is implicated as a risk factor for CSC, warranting increased vigilance from endocrinologists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.